Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate an improvement in disease-free survival (DFS) in high risk (per modified UISS criteria) subjects with RCC randomly assigned to adjuvant sunitinib 50 mg schedule 4/2: 4 weeks on, 2 weeks off for 1 year (Arm A), vs. Placebo (Arm B) after nephrectomy.
Inclusion criteria
- Adjuvant treatment of subjects with “high risk” Renal Cell Carcinoma (RCC) following nephrectomy